Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Rosenson

Showing results (1-10 of 416) with videos related to

Pageof 42
Sort By:
The American Journal of Cardiology|December 7, 2002
The rationale for combination therapyRobert S Rosenson
Drugs of Today (Barcelona, Spain : 1998)|May 10, 2003
Lipid lowering therapy as an important adjunct to stroke prevention in coronary heart disease patientsRobert S. Rosenson
Journal of Clinical Lipidology|February 10, 2026
Response to Letter to Editor titled "Pancreatitis in severe hypertriglyceridemia is a failure of temporal lipoprotein buffering-Not a problem of static lipid burden" by Nav La et alRobert S Rosenson
Current Atherosclerosis Reports|February 1, 2011
Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular riskRobert S Rosenson
Cardiology|July 31, 2009
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular riskRobert S Rosenson
Atherosclerosis|June 5, 2004
Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilitiesRobert S Rosenson
Current Opinion in Cardiology|June 16, 2005
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalitiesRobert S Rosenson
Current Atherosclerosis Reports|February 5, 2008
SPARCL: statin therapy for stroke patients is not crystal clearRobert S Rosenson
American Heart Journal|March 1, 2006
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapyRobert S Rosenson
The American Journal of Cardiology|February 20, 2007
Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitusRobert S Rosenson
Pageof 42

Showing results (1-10 of 416) with videos related to

Sort By:
Pageof 42
The American Journal of Cardiology|December 7, 2002
The rationale for combination therapyRobert S Rosenson
Drugs of Today (Barcelona, Spain : 1998)|May 10, 2003
Lipid lowering therapy as an important adjunct to stroke prevention in coronary heart disease patientsRobert S. Rosenson
Journal of Clinical Lipidology|February 10, 2026
Response to Letter to Editor titled "Pancreatitis in severe hypertriglyceridemia is a failure of temporal lipoprotein buffering-Not a problem of static lipid burden" by Nav La et alRobert S Rosenson
Current Atherosclerosis Reports|February 1, 2011
Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular riskRobert S Rosenson
Cardiology|July 31, 2009
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular riskRobert S Rosenson
Atherosclerosis|June 5, 2004
Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilitiesRobert S Rosenson
Current Opinion in Cardiology|June 16, 2005
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalitiesRobert S Rosenson
Current Atherosclerosis Reports|February 5, 2008
SPARCL: statin therapy for stroke patients is not crystal clearRobert S Rosenson
American Heart Journal|March 1, 2006
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapyRobert S Rosenson
The American Journal of Cardiology|February 20, 2007
Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitusRobert S Rosenson
Pageof 42